HC Wainwright Reiterates “Buy” Rating for Sophiris Bio, Inc. (SPHS)

HC Wainwright reaffirmed their buy rating on shares of Sophiris Bio, Inc. (NASDAQ:SPHS) in a research note released on Friday. The brokerage currently has a $6.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. Maxim Group set a $6.00 price objective on shares of Sophiris Bio and gave the stock a buy rating in a report on Thursday, June 8th. Rodman & Renshaw restated a buy rating and set a $6.00 price objective on shares of Sophiris Bio in a report on Thursday, June 1st. Finally, ValuEngine lowered shares of Sophiris Bio from a hold rating to a sell rating in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $6.60.

Sophiris Bio (NASDAQ SPHS) opened at 2.322 on Friday. The stock has a 50 day moving average of $2.02 and a 200-day moving average of $2.32. Sophiris Bio has a 1-year low of $1.80 and a 1-year high of $3.48. The firm’s market capitalization is $69.92 million.

WARNING: “HC Wainwright Reiterates “Buy” Rating for Sophiris Bio, Inc. (SPHS)” was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/hc-wainwright-reiterates-buy-rating-for-sophiris-bio-inc-sphs/1647211.html.

A hedge fund recently raised its stake in Sophiris Bio stock. Vanguard Group Inc. increased its stake in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 731,437 shares of the biopharmaceutical company’s stock after acquiring an additional 7,600 shares during the period. Vanguard Group Inc. owned about 2.43% of Sophiris Bio worth $1,609,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.01% of the company’s stock.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Analyst Recommendations for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.